Meet Jeffrey How, M.D.
Jeffrey How, MD MPH MS
Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery
About Jeffrey How
Dr. How is an Assistant Professor in the Department of Gynecologic Oncology at the University of Texas MD Anderson Cancer Center. He obtained his Medical Degree and completed his residency in Obstetrics and Gynecology at McGill University in Montreal, Canada. He received a Master of Public Health with a concentration in Epidemiology from the Harvard T.H. Chan School of Public Health in Boston. Furthermore, he completed a Master of Science in Biomedical Sciences with a concentration in Immunology at the UT Health MD Anderson Cancer Center Graduate School of Biomedical Sciences. Additionally, he completed a fellowship in Gynecologic Oncology at the University of Texas MD Anderson Cancer Center.
His research interests include immunotherapy research, innovative clinical trial designs, and translational research for the predictive markers of response and resistance for immunotherapy/targeted therapy.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2021 | The University of Texas M.D. Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, Texas, US, Biochemical Sciences, Master of Science |
| 2017 | Harvard University T.H. Chan School of Public Health, Boston, Massachusetts, US, Epidemiology, Master of Public Health |
| 2014 | McGill University School of Medicine, Montreal, CA, MD |
Postgraduate Training
| 2019-2023 | Clinical Fellowship, Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas |
| 2017-2017 | Felix Rutledge Fellowship, Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas |
| 2014-2019 | Clinical Residency, Obstetrics and Gynecology, McGill University, Montreal |
Experience & Service
Institutional Committee Activities
Core Development Team Lead, Cervical Cancer Clinical Management Algorithm Committee, 2024 - Present
Committee Member, Junior Faculty Committee, 2023 - Present
Representative of the Department of Gynecologic Oncology and Reproductive Medicine, Faculty Senate, 2023 - Present
Committee Member, Gynecologic Oncology Fellowship Program Evaluation Committee, 2023 - Present
Core Development Team Lead, Endometrial Cancer Clinical Management Algorithm Committee, 2023 - Present
Committee Member, Gynecologic Oncology Fellowship Program Admissions Committee, 2023 - Present
Clinical Quality Improvement Fellow, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Gynecologic Oncology Fellowship Program Representative, House Staff Senate, The University of Texas MD Anderson Cancer Center, 2020 - 2021
Fellowship Program Education Committee Member, The University of Texas MD Anderson Gynecologic Oncology Fellowship, 2019 - 2023
Residency Program Committee, McGill University Obstetrics and Gynecology Residency, 2018 - 2018
MORE (OB) Quality Improvement Committee, Royal Victoria Hospital Department of Obstetrics and Gynecology, 2016 - 2018
Honors & Awards
| 2023 | 2023 American Society of Clinical Oncology Annual Meeting Merit Award, Conquer Cancer, the ASCO Foundation |
| 2023 | Society of Gynecologic Oncology Bridges Research Initiative Scholar |
| 2022 - 2023 | Linda Manning Fellowship in Ovarian Cancer Research Award, The University of Texas MD Anderson Cancer Center |
| 2022 | 2022 AACR-Doreen Putrah Cancer Research Foundation Scholar-in-Training Award, Annual Meeting of the American Association for Cancer Research |
| 2022 | Recipient of the 2022 Dr. Chien-Tien Hsu Fellow Scholarship in Gynecologic Oncology, Hsu Medical Education Foundation |
| 2021 | Second place in the Oral Competition for Clinical Research, The University of Texas MD Anderson Cancer Center Trainee Research Day 2021 |
| 2021 | Thomas H. and Mayme P. Scott Fellowship in Cancer Research, The University of Texas MD Anderson Cancer Center Trainee Research Day 2021 |
| 2020 - 2021 | The University of Texas MD Anderson Gynecologic Oncology Fellowship Program Service Award |
| 2020 | Dr. Henry R. Shibata Fellowship Award, Cedars Cancer Foundation |
| 2020 | Immunology Program First-author Review Incentive Award, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences |
| 2018 - 2019 | Erin and Jane Molson Award for Excellence in Research for the academic year 2018 – 2019, McGill University Department of Obstetrics and Gynecology |
| 2017 | Award for best oral presentation for residents and fellows, 51st annual meeting of the Association of Obstetricians and Gynecologists of Quebec |
| 2017 | Brian Newton Memorial Prize for Excellence in Gynecologic Oncology for the academic year 2016 – 2017, McGill University Department of Obstetrics and Gynecology |
| 2016 - 2017 | Award for Professionalism in Obstetrics and Gynecology for the academic year 2016 – 2017, Jewish General Hospital Department of Obstetrics and Gynecology |
| 2016 - 2017 | Harvard School of Public Health Grant for studies for the academic year 2016 – 2017, Harvard School of Public Health |
| 2016 | Selected to represent McGill University for “best of the best resident research presentations”, 2016 Annual Meeting of the Association of Academic Professionals of Obstetrics and Gynecology of Canada |
| 2015 - 2016 | Award for Professionalism in Obstetrics and Gynecology for the academic year 2015 – 2016, St. Mary’s Hospital Department of Obstetrics and Gynecology |
| 2015 - 2016 | Harvard School of Public Health Grant for studies for the academic year 2015 – 2016, Harvard School of Public Health |
| 2014 | Recipient of travel grant to the Shingo Fujii Young Doctors’ Summit at the 15th biennial meeting of the International Gynecologic Cancer Society, 15th biennial meeting of the International Gynecologic Cancer Society |
| 2012 | Award for Best Scientific Oral Presentation, Young Doctors’ summit of the 14th biennial meeting of the International Gynecologic Cancer Society |
| 2011 | Recipient of the Fonds de la recherche en santé du Québec Summer Research Bursary |
| 2009 | Yale Book Award for outstanding personal character and promise of intellectual achievement, Yale Club of Montreal |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Nardo M, Xavier CB, Stephen B, How JA, Moyers J, Subbiah V, Hong DS, Naing A. Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial. J Immunother Precis Oncol 10(8):143-151, 2025. e-Pub 2025. PMID: 40212844.
- Alhalabi O, Gouda MA, Milton DR, Momin HA, Yilmaz B, Stephen B, Ejezie CL, Moyers JT, Gurses SA, How J, Fu S, Rodon J, Hong DS, Piha-Paul SA, Subbiah V, Dumbrava EE, Karp DD, Janku F, Meric-Bernstam F, Tannir NM, Naing A. A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma. Cancer Med 14(4)(4), 2025. e-Pub 2025. PMID: 39945382.
- Brodsky AL, Legarreta AF, How JA, Vuttaradhi V, Sood AK, Ramondetta LM, Gershenson DM, Hillman RT. Survival outcomes comparing minimally invasive versus open cytoreductive surgery in recurrent adult-type granulosa cell tumors. Am J Obstet Gynecol, 2025. e-Pub 2025. PMID: 39824329.
- Gouda MA, Stephen B, Tian Y, Alshawa A, Onwugaje DOC, Albittar A, Yang Y, Zarifa A, Yilmaz B, Gurses S, Sprenger A, Derbala MH, Brink A, How JA, Moyers J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Patel SP, Oliva IG. A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma. J Immunother Precis Oncol 7(4):247-254, 2024. e-Pub 2024. PMID: 39524469.
- Brodsky AL, Legarreta AF, Fellman BM, Glassman D, How J, Vuttaradhi V, Sood AK, Ramondetta LM, Gershenson D, Hillman RT. TERT promoter mutations and survival outcomes in adult-type granulosa cell tumors. Int J Gynecol Cancer, 2024. e-Pub 2024. PMID: 39395821.
- How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, Jazaeri AA. Phase II trial of pembrolizumab in combination with chemotherapy for frontline treatment of advanced epithelial ovarian cancer. Med 6(1), 2024. e-Pub 2024. PMID: 39151421.
- How, JA, Legarreta, AF, Handley, KF, Fellman, B, Foster, KI, Glassman, D, Vuttaradhi, VK, Brodsky, AL, Lawson, BC, Frumovitz, M, Westin, SN, Ramondetta, LM, Gershenson, DM, Sood, AK, Hillman, RT. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. American journal of obstetrics and gynecology 230(5):544.e1-544.e13, 2024. e-Pub 2024. PMID: 38191019.
- Bernard, L, How, JA, Patel, S, Yates, MS, Jazaeri, AA. Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab. Gynecologic oncology 180:139-145, 2024. e-Pub 2024. PMID: 38091773.
- Foster KI, Flores Legarreta A, Kamat R, Handley KF, Glassman D, How JA, Lawson BC, Westin SN, Ramondetta LM, Frumovitz M, Gershenson DM, Sood AK, Hillman RT. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. Am J Obstet Gynecol 228(6):724.e1-724.e9, 2023. e-Pub 2023. PMID: 36907533.
- How JA, Jazaeri AA, Fu S, Rodon Ahnert J, Gong J, Stephen B, Ferreira Dalla Pria H, Bhosale P, Johnson A, Yuan Y, Meric-Bernstam F, Naing A. Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers (Basel) 14(15), 2022. e-Pub 2022. PMID: 35954359.
- Marchocki Z, Cusimano MC, Clarfield L, Kim SR, Fazelzad R, Espin-Garcia O, Bouchard-Fortier G, Rossi EC, Stewart KI, Soliman PT, How JA, Gotlieb WH, Holloway RW, Ianieri MM, Cabrera S, Lim YK, Ferguson SE. Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. Am J Obstet Gynecol 225(4):367.e1-367.e39, 2021. e-Pub 2021. PMID: 34058168.
- How JA, Patel S, Fellman B, Lu KH, Hwu P, Ramondetta LM, Westin SN, Fleming ND, Soliman PT, Jazaeri AA. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol 162(1):24-31, 2021. e-Pub 2021. PMID: 33958211.
- Turkdogan S, Schnitman G, Wang T, Gotlieb R, How J, Gotlieb WH. Development of a Digital Patient Education Tool for Patients With Cancer During the COVID-19 Pandemic. JMIR Cancer 7(2):e23637, 2021. e-Pub 2021. PMID: 34101611.
- How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. Cancers (Basel) 13(5):1-18, 2021. e-Pub 2021. PMID: 33668244.
- How JA, Jazaeri AA, Soliman PT, Fleming ND, Gong J, Piha-Paul SA, Janku F, Stephen B, Naing A. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Sci Rep 11(1):3667, 2021. e-Pub 2021. PMID: 33574401.
- Kogan L, Matanes E, Wissing M, Mitric C, How J, Amajoud Z, Abitbol J, Yasmeen A, López-Ozuna V, Eisenberg N, Lau S, Salvador S, Gotlieb WH. The added value of sentinel node mapping in endometrial cancer. Gynecol Oncol 158(1):84-91, 2020. e-Pub 2020. PMID: 32349874.
- Abitbol J, Gotlieb W, Zeng Z, Ramanakumar A, Kessous R, Kogan L, Pare-Miron V, Rombaldi M, Salvador S, Kucukyazici B, Brin S, How J, Lau S. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy. Int J Gynecol Cancer 29(9):1341-1347, 2019. e-Pub 2019. PMID: 31601648.
- Wissing M, Mitric C, Amajoud Z, Abitbol J, Yasmeen A, López-Ozuna V, How J, Kessous R, Eisenberg N, Lau S, Salvador S, Gotlieb WH, Kogan L. Risk factors for lymph nodes involvement in obese women with endometrial carcinomas. Gynecol Oncol 155(1):27-33, 2019. e-Pub 2019. PMID: 31349997.
- 17Abitbol J, Lau S, Salvador S, How J, Kogan L, Kessous R, Brin S, Drummond N, Ramanakumar AV, Gotlieb R, Tatar A, Gomolin A, Gotlieb WH. A three-pronged approach to evaluating robotic surgery. Gynecol Pelvic Med:2(15):1 - 12, 2019. e-Pub 2019.
- Kessous R, How J, Abitbol J, Puzhakkal S, Kogan L, Yasmeen A, Salvador S, Gotlieb WH, Lau S. Triple tracer (blue dye, indocyanine green, and Tc99) compared to double tracer (indocyanine green and Tc99) for sentinel lymph node detection in endometrial cancer: a prospective study with random assignment. Int J Gynecol Cancer 29(7):1121-1125, 2019. e-Pub 2019. PMID: 31320490.
- Gotlieb R, Abitbol J, How JA, Ben-Brith I, Abenhaim HA, Lau SK, Basik M, Rosberger Z, Geva N, Gotlieb WH, Mintz A. Gender differences in how physicians access and process information. Gynecol Oncol Rep 27:50-53, 2019. e-Pub 2019. PMID: 30662932.
- Bougie O, Zuckerman SL, Switzer N, How J, Sey M. Influence of Resident Involvement in Obstetrics and Gynaecology Surgery on Surgical Outcomes: Systematic Review and Meta-Analysis. J Obstet Gynaecol Can 40(9):1170-1177, 2018. e-Pub 2018. PMID: 30007802.
- How JA, O'Farrell P, Amajoud Z, Lau S, Salvador S, How E, Gotlieb WH. Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis. Minerva Ginecol 70(2):194-214, 2018. e-Pub 2018. PMID: 29185673.
- How J, Boldeanu I, Lau S, Salvador S, How E, Gotlieb R, Abitbol J, Halder A, Amajoud Z, Probst S, Brin S, Gotlieb W. Unexpected locations of sentinel lymph nodes in endometrial cancer. Gynecol Oncol 147(1):18-23, 2017. e-Pub 2017. PMID: 28716308.
- How J, Gauthier C, Abitbol J, Lau S, Salvador S, Gotlieb R, Pelmus M, Ferenczy A, Probst S, Brin S, Fatnassi A, Gotlieb W. Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer. Gynecol Oncol 144(3):503-509, 2017. e-Pub 2017. PMID: 28104296.
- How J, Gotlieb WH, Press JZ, Abitbol J, Pelmus M, Ferenczy A, Probst S, Gotlieb R, Brin S, Lau S. Comparing indocyanine green, technetium, and blue dye for sentinel lymph node mapping in endometrial cancer. Gynecol Oncol 137(3):436-42, 2015. e-Pub 2015. PMID: 25870917.
- Zeng XZ, Lavoue V, Lau S, Press JZ, Abitbol J, Gotlieb R, How J, Wang Y, Gotlieb WH. Outcome of robotic surgery for endometrial cancer as a function of patient age. Int J Gynecol Cancer 25(4):637-44, 2015. e-Pub 2015. PMID: 25723778.
- How JA, Abitbol J, Lau S, Gotlieb WH, Abenhaim HA. The impact of qualitative research on gynaecologic oncology guidelines. J Obstet Gynaecol Can 37(2):138-144, 2015. e-Pub 2015. PMID: 25767946.
- Lau S, Aubin S, Rosberger Z, Gourdji I, How J, Gotlieb R, Drummond N, Eniu I, Abitbol J, Gotlieb W. Health-related quality of life following robotic surgery: a pilot study. J Obstet Gynaecol Can 36(12):1071-1078, 2014. e-Pub 2014. PMID: 25668042.
- Abitbol J, Lau S, Ramanakumar AV, Press JZ, Drummond N, Rosberger Z, Aubin S, Gotlieb R, How J, Gotlieb WH. Prospective quality of life outcomes following robotic surgery in gynecologic oncology. Gynecol Oncol 134(1):144-9, 2014. e-Pub 2014. PMID: 24796633.
- Lavoue V, Zeng X, Lau S, Press JZ, Abitbol J, Gotlieb R, How J, Wang Y, Gotlieb WH. Impact of robotics on the outcome of elderly patients with endometrial cancer. Gynecol Oncol 133(3):556-62, 2014. e-Pub 2014. PMID: 24708920.
- Drudi L, Press JZ, Lau S, Gotlieb R, How J, Eniu I, Drummond N, Brin S, Deland C, Gotlieb WH. Vaginal vault dehiscence after robotic hysterectomy for gynecologic cancers: search for risk factors and literature review. Int J Gynecol Cancer 23(5):943-50, 2013. e-Pub 2013. PMID: 23669442.
- How J, Lau S, Press J, Ferenczy A, Pelmus M, Stern J, Probst S, Brin S, Drummond N, Gotlieb W. Accuracy of sentinel lymph node detection following intra-operative cervical injection for endometrial cancer: a prospective study. Gynecol Oncol 127(2):332-7, 2012. e-Pub 2012. PMID: 22910695.
- Halliday D, Lau S, Vaknin Z, Deland C, Levental M, McNamara E, Gotlieb R, Kaufer R, How J, Cohen E, Gotlieb WH. Robotic radical hysterectomy: comparison of outcomes and cost. J Robot Surg 4(4):211-6, 2010. e-Pub 2010. PMID: 27627947.
Other Articles
- Ring KL, Mills AM, Howitt BE, Grisham RN, Euscher ED, Kim H, Klopp AH, Kolin DL, McCluggage W, Mirkovic J, Park KJ, Aoun E, Awujo C, Son J, Mok SC, Ferri-Borgogno S, Hong DS, Hoang L, Jazaeri AA, How JA, Lu KH Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics. Gynecol Oncol 197:57-65, 2025. PMID: 40279981.
- How JA, Jazaeri AA Integrating CTLA-4/PD-1 blockade into cervical cancer management: Results of COMPASSION-16. Med 6(1):100558, 2025. PMID: 39798550.
- How JA, Jazaeri AA, Westin SN, Lawson BC, Klopp AH, Soliman PT, Lu KH Translating biological insights into improved management of endometrial cancer. Nat Rev Clin Oncol 21(11):781-800, 2024. PMID: 39198622.
- How, JA, Jazaeri, AA Immunotherapy in locally advanced cervical cancer. Med 5(6):487-489, 2024. PMID: 38878765.
- Batman S, Rauh-Hain JA, Grinsfelder MO, Harrison R, Avila M, Cun H, How JA, Tandon N, Wang X, Hinchcliff E, Jazaeri AA, Schmeler KM Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report. Case Rep Oncol 16(1):273-278, 2023. PMID: 37123608.
- How JA, Frumovitz M, Stewart KI, Soliman PT Lymphatic Mapping and Sentinel Node Biopsy in High-Grade Uterine Cancers. Curr Oncol Rep 24(11):1521-1529, 2022. PMID: 35781863.
- Schnitman G, Wang T, Kundu S, Turkdogan S, Gotlieb R, How J, Gotlieb W The role of digital patient education in maternal health: A systematic review. Patient Educ Couns 105(3):586-593, 2022. PMID: 34183217.
- How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs 39(3):829-835, 2021. PMID: 33415580.
- How JA, Siedel JH, Shafer A Post-operative gastroparesis following carbohydrate loading in a diabetic patient. Gynecol Oncol Rep 36:100714, 2021. PMID: 33644283.
- Nguyen DB, How J, Ziegler C, Madar J Acute Respiratory Distress Syndrome After Uterine Artery Embolization. Obstet Gynecol 132(4):956-959, 2018. PMID: 30204705.
Abstracts
- Clark HD, Lito K, Fellman B, Fix SM, Knisely A, Fleming ND, Shafer A, Sims T, Soliman PT, Taylor J, Westin SN, Jazaeri AA, How JA. Efficacy pembrolizumab and lenvatinib monotherapy and combination therapy in patients with platinum-resistant high-grade serous ovarian cancer. Annual Meeting on Women's Cancer.
- How JA, Abitbol J, Lau S, Gotlieb WH, Abenhaim HA. The Impact of Qualitative Research on Gynecologic Oncology Guidelines. Annual Clinical and Scientific Meeting of the Society of Obstetricians and Gynecologists of Canada.
- How JA, Gotlieb W, Press J, Abitbol J, Pelmus M, Ferenczy A, Probst S, Stern J, Gotlieb R, Brin S, Lau S. Sentinel lymph node detection comparing intra-operative cervical injection of indocyanine green, technetium, and blue dye for endometrial cancer. International Gynecologic Cancer Society Global Meeting.
- How JA, Boldeanu I, Abitbol J, Lau S, Salvador S, Gotlieb R, Gotlieb W. Unexpected areas of sentinel lymph node detection following intra-operative cervical injection in endometrial cancer. Annual Meeting on Women's Cancer.
- How JA, Gauthier C, Abitbol J, Lau S, Salvador S, Gotlieb R, Gotlieb W. Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer. Annual Meeting on Women's Cancer.
- How JA, Boldeanu I, Abitbol J, Lau S, Salvador S, Gotlieb R, Gotlieb W. Outcomes of patients with pre-operative grade 1 endometrial cancer and sentinel lymph node mapping. Annual Meeting on Women's Cancer.
- How JA, Boldeanu I, Lau S, Salvador S, How E, Gotlieb R, Abitbol J, Gotlieb W. Mapping des ganglions sentinelles et cancer de l’endomètre: la valeur de l’injection intra-cervicale. 51st annual meeting of the Association of Obstetricians and Gynecologists of Quebec.
- Bougie O, Zuckerman S, Switzer N, How J, Sey M. Influence of Resident Involvement in Obstetrics and Gynecology Surgery on Surgical Outcomes: Systematic Review and Meta-Analysis. Annual Clinical and Scientific Meeting of the Society of Obstetricians and Gynecologists of Canada.
- How JA, Abitbol J, Lau S, Salvador S, Gotlieb R, Gotlieb W. Survival Outcomes of patients with high-grade endometrial cancer undergoing sentinel lymph node mapping. Annual Meeting on Women's Cancer.
- How JA, Gotlieb R, Turkdogan S, Gotlieb WH. The Use of a Multilingual Animated Pregnancy Guide as an adjunct in prenatal care. Annual Clinical and Scientific Meeting of the Society of Obstetricians and Gynecologists of Canada.
- How JA, Timms K, Jazaeri A, Lu K, Yates MS. Characterization of homologous recombination deficiency in uncommon epithelial ovarian cancer subtypes. Annual Meeting on Women's Cancer (virtual).
- How JA, Jazaeri A, Fu S, Rodon Ahnert J, Gong J, Meric-Bernstam F, Naing A. Characteristics and clinical outcomes of patients with recurrent microsatellite stable endometrial cancer undergoing early phase immunotherapy clinical trials. International Gynecologic Cancer Society Annual Global Meeting (virtual).
- How JA, Dang M, Euscher E, Yates M, Peng W, Patel S, Lu K, Hwu P, Wang L, Jazaeri A. The impact of the tumor immune microenvironment on response to pembrolizumab in patients with microsatellite instability-high endometrial cancer. American Association for Cancer Research Virtual Special Conference: Endometrial Cancer: New Biology driving research and treatment (virtual).
- How JA, Dang M, Euscher E, Yates M, Peng W, Patel S, Lu K, Hwu P, Wang L, Jazaeri A. The tumor immune microenvironment shapes response to pembrolizumab in microsatellite instability-high endometrial cancer. Annual Meeting on Women's Cancer.
- How JA, Patel S, Fellman B, Lu K, Ramondetta L, Westin SN, Fleming N, Soliman PT, Jazaeri AA. The use of pembrolizumab and lenvatinib combination therapy in endometrial cancer: an examination of toxicity and treatment efficacy in clinical practice. Annual Meeting on Women's Cancer (virtual).
- How JA, Fellman B, Westin SN, Sood AK, Fleming ND, Yuan Y, Shafer A, Zand B, Schmeler KM, Nick A, Lu KH, Coleman R, Jazaeri AA. The feasibility and efficacy of pembrolizumab in combination with chemotherapy in patients undergoing frontline treatment of ovarian cancer. International Gynecologic Cancer Society Annual Global Meeting (virtual).
- How JA, Dang M, Ferri-Borgogno S, Euscher E, Yates M, Peng W, Patel S, Burks JJ, Vletic I, Gomez J, Lu K, Mok SC, Wang L, Jazaeri A. Predictors of innate resistance to pembrolizumab in patients with microsatellite instability-high endometrial cancer. AACR Annual Meeting.
- How JA, Westin S, Sims T, Lito K, Celestino J, Rangel KM, Peng W, Wang L, Jazaeri AA. Trial in progress - Uncovering Mechanisms of Response of Pembrolizumab and Lenvatinib for the Treatment of Platinum resistant High grade Serous Ovarian Cancer. Annual Meeting of the American Society of Clinical Oncology.
- How JA, Flores Legarreta A, Fellman B, Handley KF, Foster KI, Glassman D, Lawson B, Ramondetta LM, Gershenson DM, Sood AK, Hillman RF. Impact of cytoreductive surgery on survival outcomes for recurrent adult-type granulosa cell tumors of the ovary. Annual Meeting of the American Society of Clinical Oncology.
- How JA, Rauh-Hain JA, Grinsfelder M, Rangel KM, Roder S, Shafer A, Schmeler K, Boruta D, Fleming ND, Lu KH, Vining DJ, Frumovitz M, Jazaeri AA. Trial in progress - Triage of advanced cervical cancer through immunotherapy induction (TRACTION). Annual Meeting of the American Society of Clinical Oncology.
- Aoun E, Euscher E, Awujo C, Lawson B, Jazaeri A, Lu K, How JA. Clinicopathologic features of mesonephric-like adenocarcinoma of the ovary and peritoneum. Annual Meeting on Women's Cancer.
Book Chapters
- How JA, Abitbol J, Gotlieb WH. Minimally invasive surgery in ovarian cancer. In: Surgery for ovarian cancer. 4th. CRC Press, 2023.
- How JA, Patel A, Jazaeri AA. Immuno-oncology for Gynecologic Malignancies. In: Immunotherapy. 4th. Springer Nature, 193-232, 2022.
- How J, Patel A, Jazaeri A. Immuno-oncology for Gynecologic Malignancies. In: Immunotherapy. 3rd. Springer Nature, 2020.
- How J, Gotlieb WH. Sentinel lymph node evaluation in endometrial cancer. In: Uterine Cancer: Diagnosis & Management, 2014.
Selected Presentations & Talks
Local Presentations
- 2024. Exciting New Clinical Trials to Watch Out for in 2024. Invited. Gynecologic Oncology and Reproductive Medicine Grand Rounds. Houston, Texas, US.
- 2022. From Bedside to Bench and Back: Deciphering the Tumor Microenvironment to unravel mechanisms of Immunotherapy Resistance in Endometrial Cancer. Invited. Gynecologic Oncology and Reproductive Medicine Grand Rounds. Houston, Texas, US.
- 2018. Risk factors for synchronous primary ovarian and endometrial cancer in a population-based sample. Conference. McGill University Department of Obstetrics & Gynecology Research Day. Montreal, Quebec, CA.
- 2017. Survival outcomes of sentinel lymph node mapping in high-risk endometrial histologies. Conference. McGill University Department of Obstetrics & Gynecology Research Day. Montreal, Quebec, CA.
National Presentations
- 2024. Minimally-invasive vs open radical hysterectomy for early-stage cervical cancer. Invited. 72nd Annual Meeting of the Society of Pelvic Surgeons. Houston, Texas, US.
- 2024. Management of Immunotherapy toxicities. Invited. 2024 Annual Meeting of the Felix Rutledge Society. Fort Lauderdale, Florida, US.
- 2016. The impact of the sentinel lymph node mapping in the management of pre-operative grade 1 endometrial cancer. Conference. Association of Academic Professionals in Obstetrics and Gynecology of Canada Annual Meeting. Toronto, Ontario, CA.
International Presentations
- 2025. Phase II trial of immune checkpoint blockade with or without ELI-002 7P for the treatment of recurrent KRAS-mutated endometrial and ovarian cancer. Invited. 2025 Gynecologic Mesonephric-like Adenocarcinoma Consortium Meeting. Houston, US.
- 2024. Novel KRAS vaccines. Invited. 2024 Gynecologic Mesonephric-like adenocarcinoma Consortium Meeting. Houston, US.
- 2022. Immunotherapy in Gynecologic Cancer: A New Era of Cancer Therapy. Invited. Department of Obstetrics and Gynecology Grand Rounds. Montreal, CA.
- 2022. Sentinel Lymph Node Mapping in Endometrial Cancer. Invited. 2022 Annual Conference of the West Lake Summit of International Gynecological Oncology & Zhejiang Gynecologic Cancer Society (Virtual), CN.
- 2021. Immunotherapy in Gynecologic Cancer: A New Era of Cancer Therapy. Invited. Department of Obstetrics and Gynecology Grand Rounds. Montreal, CA.
Patient Reviews
CV information above last modified May 06, 2025